亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy

医学 内科学 肺癌 外显子 肿瘤科 化疗 癌症研究 基因 遗传学 生物
作者
Anna Minchom,Santiago Viteri,Lyudmila Bazhenova,Shirish M. Gadgeel,Sai‐Hong Ignatius Ou,José Trigo,Joshua Bauml,Daniel Backenroth,Archan Bhattacharya,Tracy Li,Parthiv J. Mahadevia,Nicolas Girard
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:168: 74-82 被引量:33
标识
DOI:10.1016/j.lungcan.2022.03.005
摘要

BACKGROUND: In the single-arm CHRYSALIS study, amivantamab showed durable responses and manageable safety in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who progressed on prior platinum-based chemotherapy. External controls can provide context for interpreting amivantamab efficacy. METHODS: External controls were selected from three US-based databases (ConcertAI, COTA, and Flatiron). Key inclusion criteria were diagnosis of EGFR ex20ins advanced NSCLC, prior platinum-based chemotherapy, and performance status score ≤ 1. Duplicate external controls were identified using a tokenization procedure and removed, and adjustment for differences in baseline characteristics between amivantamab-treated and external control cohorts was achieved using propensity score weighting. RESULTS: Amivantamab-treated and pooled external control cohorts included 81 and 125 patients, respectively. Baseline characteristics were generally similar across cohorts, except more amivantamab-treated patients were Asian (56% vs 13%). Most common therapies received by external controls were non-platinum-based chemotherapy (25.1%), immuno-oncology therapies (24.2%), EGFR tyrosine kinase inhibitors (16.3%), and platinum-based chemotherapy (16.3%). Overall response rate was 40% among amivantamab-treated patients and 16% among external controls. Amivantamab-treated patients had longer progression-free survival (median 8.3 vs 2.9 months; hazard ratio [HR; 95% CI]: 0.47 [0.34-0.65]), time to next therapy (median 14.8 vs 4.8 months; HR [95% CI]: 0.40 [0.28-0.57]), and overall survival (median 22.8 vs 12.8 months; HR [95% CI]: 0.49 [0.31-0.77]) than external controls. Results were consistent in sensitivity analyses comparing each external control dataset against the amivantamab-treated group separately. CONCLUSION: Among post-platinum patients with EGFR ex20ins advanced NSCLC, those treated with amivantamab had improved outcomes, including 10-month longer overall survival, versus external controls.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开心饼干完成签到,获得积分10
7秒前
9秒前
兴奋的疾完成签到,获得积分10
43秒前
47秒前
失眠忆曼完成签到,获得积分10
50秒前
染染完成签到 ,获得积分10
52秒前
53秒前
隐形曼青的应助被2589采纳,获得10
58秒前
不吃垃圾食品完成签到,获得积分10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
不安的晓露完成签到,获得积分10
1分钟前
可靠的平松完成签到,获得积分10
1分钟前
1分钟前
1分钟前
如意嘉熙完成签到,获得积分10
1分钟前
沉默的黎昕完成签到,获得积分10
1分钟前
2分钟前
2分钟前
从容美女发布了新的文献求助10
2分钟前
2分钟前
amiee发布了新的文献求助10
2分钟前
李爱国的应助被wubin69采纳,获得10
2分钟前
愤怒的若颜完成签到,获得积分10
2分钟前
Youy完成签到 ,获得积分10
2分钟前
2分钟前
wubin69发布了新的文献求助10
2分钟前
魔幻萃完成签到,获得积分10
2分钟前
典雅的醉易完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
3分钟前
科研通AI6.3的应助被wubin69采纳,获得10
3分钟前
独特珩完成签到,获得积分10
3分钟前
xiaoshulin完成签到,获得积分10
3分钟前
传奇3的应助被炙热白开水采纳,获得20
3分钟前
NeoAir完成签到 ,获得积分10
3分钟前
曹博完成签到 ,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185215
求助须知:如何正确求助?哪些是违规求助? 9574085
关于积分的说明 21834197
捐赠科研通 7782763
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558801
邀请新用户注册赠送积分活动 2481237